RDNT

Radnet, Inc. 10-Q Summary: Quarter Ended March 31, 2007

Business Context and Reporting Period

This Form 10-Q covers the three-month period ended March 31, 2007. Radnet, Inc. operates a network of 132 diagnostic imaging facilities across seven states, providing services including MRI, CT, PET, and X-ray. The reporting period includes the full impact of the Radiologix, Inc. acquisition completed on November 15, 2006. The company operates as a single segment and is currently in a stockholders' deficit position.

Key Financial Metrics

Margin Analysis: Operating margin was 5.4% for Q1 2007 compared to 11.0% in Q1 2006. The provision for bad debts increased significantly to 7.1% of revenue, driven by the Radiologix acquisition.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 167% to $105.8 million, primarily due to the inclusion of Radiologix ($64.8 million contribution). Organic revenue growth excluding Radiologix was $1.4 million.
• Expense Increases: Operating expenses rose 173% to $100.1 million. Key drivers included:
  • Salaries: Increased $25.6 million, largely due to Radiologix integration.
  • Stock-Based Compensation: Increased $2.0 million to $2.2 million, driven by a $1.7 million one-time charge for the accelerated vesting of executive warrants triggered by stock price performance.
  • Bad Debt Provision: Increased $6.1 million to $7.6 million (7.1% of revenue) due to higher bad debt rates inherent in Radiologix's hospital payer mix.
• Interest Expense: Increased 149% to $10.9 million due to the $360 million debt load assumed in the Radiologix acquisition and amortization of deferred financing costs.
• Debt Structure: The company refinanced its debt in November 2006 into a $405 million senior secured credit facility (GE Commercial Finance), consisting of a $45 million revolver, $225 million term loan, and $135 million second lien term loan.

Outlook, Risks, and Unusual Items

• Liquidity: Management believes it will generate sufficient cash to satisfy obligations for the next 12 months through strategic plans and debt restructuring, despite operating in a capital-intensive industry with cash flows insufficient to fund all capital requirements.
• Internal Control Weakness: The company identified a material weakness in internal controls over financial reporting. Specifically, there were insufficient processes to identify non-routine accounting matters and a lack of technical accounting expertise. The company has engaged an external consulting firm (MorganFranklin) to remediate this issue.
• Unusual Items:
  • Warrant Vesting: A $1.7 million non-cash charge was recorded for the full vesting of executive warrants.
  • Acquisition Costs: $538,000 in severance costs related to Radiologix integration.
  • Listing Fee: $120,000 one-time fee for NASDAQ listing.
• Risks: Significant risks include substantial indebtedness, dependence on third-party reimbursement rates (specifically DRA reductions effective Jan 2007), and the successful integration of Radiologix operations.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the minimum fixed charge coverage ratio and leverage ratios under the new $405 million GE credit facility.
• Bad Debt Trends: Monitor the provision for bad debts, which rose to 7.1% of revenue, to ensure it does not erode operating margins further.
• Internal Control Remediation: Confirm the progress of hiring qualified accounting personnel and the effectiveness of the engagement with MorganFranklin to resolve the material weakness.
• Stock-Based Compensation: Review future quarters for potential volatility in expenses related to warrant vesting conditions tied to stock price performance.
• Cash Burn: Track the $1.2 million cash balance against the $5.7 million net cash used in investing activities to assess immediate liquidity needs.